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ABSTRACT
The survival of 90% of a tumor-bearing population treated with the complex Rh2(CF3CONH)4 was
examined and the pharmacological parameter Survgo determined. Histopathological alterations raised for this
drug in several tissues were studied in Balb-c mice. A Survgo dose of 3.8x 10
.5 mol/kg was found.
INTRODUCTION
The use of rhodium (II) dimers as possible antitumoral agents has been investigated, and the recent
literature reports a number of examples of these complexes which could overcome the toxicities of the
carboxylates initially proposed [1]. Relatively few data are available about the biodistribution,
pharmacokinetics and histopathology of the rhodium (II) dimer complexes. Souza and coworkers [2]
investigated the distribution of rhodium in mice submitted to treatment with the adduct of rhodium
propionate and sodium isonicotinate, by means of ICP-AES. Craciunescu and coworkers [3] performed a
study of the biological activity, nephro, hepato and hematotoxicity of adducts of rhodium(II) and iridium(II)
dimers with classical organic antimalarial drugs. Also, these authors described the renal histopathology atter
the administration of the complex Rhz(CH3COO)4(mepacrine)2.
Recently, the pharmacological parameters ICs0 (against Ehrlich ascites and U937 and K562 human
leukemia cells) and LDs0 (in male Balb-c mice) of the complex Rhz(CF3CONH)4 (tfacam) were reported. The
LDso of tfacam was close to the value obtained for cisplatin in similar conditions (cf. [4] and references
therein]. These results encouraged subsequent studies in the biological destinations of this and other rhodium
(II) complexes. In this work, the pharmacological parameter Survo was determined (def’med as the dose that
allows the survival of90% of the tumor-treated animals [5]) of the drug tfacam. The histopathological study
of brain, blood, kidney, spleen, liver, lungs, bone marrow, testes and ovary tissues from Balb-c mice treated
with this complex are also presented.
MATERIALS AND METHODS
The complex tfacam was synthesized and suspended in an aqueous solution (5% of TweenTM-80) as
described in [4].
a) Survival test: Male Balb-c mice were inoculated i.p. with 5xl05 cells of Ehrlich tumor and treated
i.p. after 24 h with different volumes of a 1.2xl 0 M tfacam solution. Alive and dead animals were counted
after 39 days.
b) Histopathological test" Fourteen healthy Balb-c mice were divided in three groups. Two animals
received i.p. 500 laL of saline (control group). Seven animals received 500 laL of the aqueous TweenTM-80
solution. Five animals received 500 laL of a 2.0x10
"3 M tfacam solution so that each one of them had
approximately the Survgo dose.
The mice were sacrificed to collect tissue (heart, lungs, blood, liver, kidneys, testes, ovary, brain and
bone marrow) after 25 days. Those parts were kept in a 10% formol solution and then in blocks of paraffin
and finally in slides to be observed in hematoxylin-eosin coloration in an optic microscope. No animals died
for toxic effects of the drug during this period.
RESULTS
a) Survival tes.__.2t: Table shows the counts after the experimental period.
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Table I: Determination of the parameter Su.rv9o
Dose
..(X 10__Smol/kg) numbe_r 3 da2cs ,survival,,_
Control" 7 7 0
1.0 7 2 71
1.5 8 2 75
2.1 5 80
2.6 8 84
only Tween"--80
From these data, it was found a Survgo value of 3.8x 10
.5 mol/kg for the complex tfacam.
b) His_topathological test: No differences were observed between the control group and the group of
animals that received only TweenTM-80 solution.
The mice that received the rhodium drug showed the abnormalities reported in Table II.
Table II: Histo_pathological.a_lte(ations_observed inthe__ mice treated.with the Surv9o dOSe oftfacam
_A_n_im_a1_ Histopathological alterations
no alterations
2 hepatic necrosis
3 hepatic necrosis; hemorragic points in the lungs;
tubular necrosis in the kidneys
4 hepatic necrosis; pneumonia; tubular necrosis in the
kidneys; focal brain dismielinization
5 tubular necrosis in the kidneys
DISCUSSION
Craciunescu et al. [3] used half of the LDs0 of the drug Rh2(CH3COO)4(mepacrine): and found
alterations described as light to moderate nephrotoxicity, and no hepatotoxicity.
With the i.p. injection of tfacam solution in the range of 1.0 to 2.6x10
.5 mol/kg, a linear dependence
between the survival rate and the dose was obtained. The extrapolation to 90% afforded us the value of Survo
3.8x10
5 mol/kg. However, this dose is close to the LDs0 of the drug (4.8x10
5 mol/kg [4]). The injection
of the Survgo dose in five animals didn’t cause any deaths. The toxic effects appeared mainly in the liver and
kidneys.
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